Evidence map›Paper›PMID 37365509›Full record

ArticleMolecular medicine (Cambridge, Mass.)2023

High mobility group box 1 and a network of other biomolecules influence fatigue in patients with Crohn's disease.

Ingeborg Kvivik, Tore Grimstad, Kjetil Bårdsen, Grete Jonsson, Jan Terje Kvaløy, Roald Omdal

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ingeborg KvivikResearch Department, Stavanger University Hospital, P.O. Box 8100, 4068, Stavanger, Norway.
Tore GrimstadUnit of Gastroenterology, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.
Kjetil BårdsenResearch Department, Stavanger University Hospital, P.O. Box 8100, 4068, Stavanger, Norway.
Grete JonssonDepartment of Medical Biochemistry, Stavanger University Hospital, Stavanger, Norway.
Jan Terje KvaløyResearch Department, Stavanger University Hospital, P.O. Box 8100, 4068, Stavanger, Norway.
Roald OmdalResearch Department, Stavanger University Hospital, P.O. Box 8100, 4068, Stavanger, Norway. roald.omdal@sus.no.ORCID 0000-0002-6051-4658
Stavanger University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFatigue is common in patients with chronic inflammatory and autoimmune diseases, often with a severe impact on the patient's daily life. From a biological point of view, fatigue can be regarded as an element of the sickness behavior response, a coordinated set of responses induced by pathogens to enhance survival during an infection and immunological danger. The mechanisms are not fully understood but involve activation of the innate immune system, with pro-inflammatory cytokines, in particular interleukin (IL)-1β, acting on cerebral neurons. These mechanisms are also active during chronic inflammatory conditions. High mobility group box 1 (HMGB1) protein has interleukin-1 like properties and is a strong inducer of innate immune responses. Its role in generation of fatigue is not clarified. Emerging evidence indicates that also other biomolecules may influence sickness behavior. We aimed to elucidate how HMGB1 influences fatigue in patients with Crohn's disease, and how the protein interacts with other candidate biomarkers of fatigue.

methodsIn 56 patients with newly diagnosed Crohn's disease, fatigue was evaluated using three different fatigue instruments: the fatigue visual analog scale (fVAS), Fatigue Severity Scale (FSS), and the vitality subscale of Medical Outcomes Study Short-Form Health Survey (SF-36vs). The biochemical markers IL-1 receptor antagonist (RA), soluble IL-1 receptor type 2 (sIL-RII), heat shock protein 90 alpha (HSP90α), HMGB1, anti-fully reduced (fr)HMGB1 antibodies (abs), hemopexin (HPX), and pigment epithelium-derived factor (PEDF) were measured in plasma. Multivariable regression and principal component analyses (PCA) were applied.

resultsMultivariable regression analyses revealed significant contributions to fatigue severity for HMGB1 in the FSS model, HSP90α in the fVAS model and IL-1RA in the SF-36vs model. Depression and pain scores contributed to all three models. In PCA, two components described 53.3% of the variation. The "inflammation and cellular stress dimension" was dominated by IL-1RA, sIL-1RII, HSP90α, HPX, and PEDF scores, where the "HMGB1 dimension" was dominated by HMGB1, anti-frHMGB1 abs, and fVAS scores.

conclusionThis study supports the hypothesis that HMGB1 and a network of other biomolecules influence fatigue severity in chronic inflammatory conditions. The well-known association with depression and pain is also acknowledged.

Indexed as

Crohn DiseaseHMGB1 ProteinChronic DiseaseFatigueHumansInflammationInterleukin 1 Receptor Antagonist ProteinPainReceptors, Interleukin-1HMGB1 ProteinHMGB1 protein, humanInterleukin 1 Receptor Antagonist ProteinReceptors, Interleukin-1Cellular defenseChronic inflammationCrohn’s diseaseFatigueHMGB1Principal component analysisSickness behavior

Identifiers

PMID37365509
PMCPMC10291761
OpenAlexW4382136124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.